Methoxetamine‐related deaths in the UK: an overview
Stefania Chiappini, Hugh Claridge, John Corkery, Christine Goodair, Barbara Loi, Fabrizio Schifano
Human Psychopharmacology: Clinical and Experimental July 1, 2015 DOI: 10.1002/hup.2422 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case series Case report Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Fatalities involving methoxetamine in the UK and Islands (Isle of Man, Jersey, Guernsey) |
| Citations | 45 |
| Key findings | Methoxetamine was directly implicated in four of eight fatalities and likely influenced two others, with most decedents being young White males who used MXE with other substances. |
Abstract
Objective: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011-2013, presented at the Second International Conference on Novel Psychoactive Substances.
Methods: Fatalities involving MXE were extracted from the database of the National Programme on Substance Abuse Deaths, which receives information on drug-related deaths from Coroners in the UK and Islands (Isle of Man, Jersey, Guernsey) and other data suppliers.
Results: Eight cases, received by 3 September 2013, in which MXE was found at post-mortem and/or directly implicated in the death and/or mentioned in the Coroner's verdict are described. The median age at death was 27 years, with the majority of White ethnicity (6/8) and male (7/8). MXE was used together with other substances in 7/8 cases. MXE was found at post-mortem in all cases, directly implicated in the deaths of four and likely to have had an influence in two.
Conclusions: More research needs to be conducted into its health effects and toxicity potential. Health care professionals should be made aware of the potential health harms of MXE, in order to develop early intervention measures and minimise the number of MXE-related poisonings and fatalities.
Citations in the library
Cited by 15
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat Brain Research Bulletin May 4, 2016
- 4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study Human Psychopharmacology: Clinical and Experimental May 1, 2017
- Novel psychoactive substances (NPS): clinical and pharmacological issues Drugs and Alcohol Today February 24, 2015
- Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study Journal of Psychoactive Drugs February 9, 2019
and 10 more in the library
Cites 8
- Ketamine use: a review Addiction July 21, 2011
- Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. Journal of Medical Toxicology March 1, 2012
- "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Science International March 20, 2011
- Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet Journal of Psychoactive Drugs July 1, 2013
- Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order). Emergency Medicine Journal 2014
and 3 more in the library